Compare $INTI vs $TCRX | Chartloom

Compare

$INTI vs $TCRX

Inhibitor Therapeutics Inc · TScan Therapeutics Inc

INTI

Inhibitor Therapeutics Inc

TCRX

TScan Therapeutics Inc

Compare $INTI vs $TCRX

Comparing Inhibitor Therapeutics Inc and TScan Therapeutics Inc

INTIInhibitor Therapeutics Inc

TCRXTScan Therapeutics Inc

INTIInhibitor Therapeutics Inc

Market cap

$17M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

108.5%

52W performance

127.9%

FCF yield

-19.1%

TCRXTScan Therapeutics Inc

Market cap

$16M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

8.85x

Rev growth (TTM)

2.2%

YTD performance

-76.7%

52W performance

-88.0%

FCF yield

-761.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

INTI

TCRX

Detailed metrics comparison

INTI

Inhibitor Therapeutics Inc

TCRX

TScan Therapeutics Inc

Market Cap

INTI$17M

TCRX$16M

Enterprise Value

INTI$16M

TCRX$-52M

Price

INTI$0.10

TCRX$0.24

P/E Ratio

INTIN/A

TCRXN/A

P/S Ratio

INTI4.25x

TCRX2.19x

EV/Sales

INTI4.12x

TCRX-7.29x

EV/EBITDA

INTI1.61x

TCRX0.00x

P/B Ratio

INTI4,922.43x

TCRX0.31x

P/FCF Ratio

INTIN/A

TCRXN/A

EV/FCF

INTI-5.09x

TCRX0.44x

PEG Ratio

INTIN/A

TCRXN/A

Forward P/E (NTM)

INTIN/A

TCRXN/A

Forward P/S (NTM)

INTIN/A

TCRX8.85x

Revenue (TTM)

INTI$0

TCRX$7M

Revenue Growth (YoY)

INTIN/A

TCRX2.2%

Forward Rev Growth

INTI0.0%

TCRX42.6%

Gross Margin (TTM)

INTI20.9%

TCRX0.0%

Operating Margin (TTM)

INTI0.0%

TCRX0.0%

EBITDA Margin (TTM)

INTI0.0%

TCRX-1626.5%

Net Margin (TTM)

INTI0.0%

TCRX-1655.4%

FCF Margin (TTM)

INTIN/A

TCRX-1665.6%

Net Income (TTM)

INTI$-3M

TCRX$-118M

FCF (TTM)

INTI$-3M

TCRX$-118M

EPS (TTM)

INTI$0.00

TCRX-$0.91

ROE (TTM)

INTI-33792.0%

TCRX-10872.0%

ROA (TTM)

INTI-12210.0%

TCRX-5447.0%

ROIC (TTM)

INTI-33792.0%

TCRX-8356.0%

Cash

INTI$516K

TCRX$100M

Debt

INTI$0

TCRX$33M

Net Cash/Debt

INTI$516K

TCRX$67M

Current Ratio (TTM)

INTI3.36x

TCRX3.37x

Quick Ratio (TTM)

INTI2.95x

TCRX3.23x

Debt/Equity (TTM)

INTI0.00x

TCRX0.47x

Debt/Assets (TTM)

INTI0.0%

TCRX0.0%

Interest Coverage (TTM)

INTIN/A

TCRXN/A

Net Debt/EBITDA (TTM)

INTI0.00x

TCRX0.00x

Beta

INTI-0.79

TCRX1.19

52W Performance

INTI127.9%

TCRX-88.0%

YTD Performance

INTI108.5%

TCRX-76.7%

% from 52W High

INTI-21.0%

TCRX-90.7%

% from 52W Low

INTI180.0%

TCRX6.1%

Asset Turnover (TTM)

INTI0.50x

TCRX0.03x

FCF Yield (TTM)

INTI-19.1%

TCRX-761.5%

Earnings Yield (TTM)

INTI-15.9%

TCRX-756.8%

Dividend Yield (TTM)

INTIN/A

TCRXN/A

Rule of 40

INTI0.0

TCRX-1,663.4

EV/GP/RG

INTIN/A

TCRXN/A

Ticker research

View INTI research View TCRX research

Metric	INTI Inhibitor Therapeutics Inc	TCRX TScan Therapeutics Inc
Market & Valuation
Market Cap	$17M	$16M
Enterprise Value	$16M	$-52M
Price	$0.10	$0.24
P/E Ratio	N/A	N/A
P/S Ratio	4.25x	2.19x
EV/Sales	4.12x	-7.29x
EV/EBITDA	1.61x	0.00x
P/B Ratio	4,922.43x	0.31x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.09x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	8.85x
Revenue & Growth
Revenue (TTM)	$0	$7M
Revenue Growth (YoY)	N/A	2.2%
Forward Rev Growth	0.0%	42.6%
Profitability
Gross Margin (TTM)	20.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1626.5%
Net Margin (TTM)	0.0%	-1655.4%
FCF Margin (TTM)	N/A	-1665.6%
Net Income (TTM)	$-3M	$-118M
FCF (TTM)	$-3M	$-118M
EPS (TTM)	$0.00	-$0.91
ROE (TTM)	-33792.0%	-10872.0%
ROA (TTM)	-12210.0%	-5447.0%
ROIC (TTM)	-33792.0%	-8356.0%
Financial Health
Cash	$516K	$100M
Debt	$0	$33M
Net Cash/Debt	$516K	$67M
Current Ratio (TTM)	3.36x	3.37x
Quick Ratio (TTM)	2.95x	3.23x
Debt/Equity (TTM)	0.00x	0.47x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.79	1.19
52W Performance	127.9%	-88.0%
YTD Performance	108.5%	-76.7%
% from 52W High	-21.0%	-90.7%
% from 52W Low	180.0%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.03x
FCF Yield (TTM)	-19.1%	-761.5%
Earnings Yield (TTM)	-15.9%	-756.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,663.4
EV/GP/RG	N/A	N/A
Ticker research	View INTI research	View TCRX research

Valuation

P/S Ratio

TCRX

2.19x

INTI

4.25x

EV/FCF

INTI

-5.09x

TCRX

0.44x

Growth & revenue

Revenue Growth TTM

TCRX

2.2%

Forward Revenue Growth

TCRX

42.6%

INTI

0.0%

Profitability & performance

Gross Margin

INTI

20.9%

TCRX

0.0%

ROE

TCRX

-10872.0%

INTI

-33792.0%

FCF Yield %

INTI

-19.1%

TCRX

-761.5%

52-Week Performance

INTI

127.9%

TCRX

-88.0%

Detailed metrics comparison

INTI

Inhibitor Therapeutics Inc

TCRX

TScan Therapeutics Inc

Market Cap

INTI$17M

TCRX$16M

Enterprise Value

INTI$16M

TCRX$-52M

Price

INTI$0.10

TCRX$0.24

P/E Ratio

INTIN/A

TCRXN/A

P/S Ratio

INTI4.25x

TCRX2.19x

EV/Sales

INTI4.12x

TCRX-7.29x

EV/EBITDA

INTI1.61x

TCRX0.00x

P/B Ratio

INTI4,922.43x

TCRX0.31x

P/FCF Ratio

INTIN/A

TCRXN/A

EV/FCF

INTI-5.09x

TCRX0.44x

PEG Ratio

INTIN/A

TCRXN/A

Forward P/E (NTM)

INTIN/A

TCRXN/A

Forward P/S (NTM)

INTIN/A

TCRX8.85x

Revenue (TTM)

INTI$0

TCRX$7M

Revenue Growth (YoY)

INTIN/A

TCRX2.2%

Forward Rev Growth

INTI0.0%

TCRX42.6%

Gross Margin (TTM)

INTI20.9%

TCRX0.0%

Operating Margin (TTM)

INTI0.0%

TCRX0.0%

EBITDA Margin (TTM)

INTI0.0%

TCRX-1626.5%

Net Margin (TTM)

INTI0.0%

TCRX-1655.4%

FCF Margin (TTM)

INTIN/A

TCRX-1665.6%

Net Income (TTM)

INTI$-3M

TCRX$-118M

FCF (TTM)

INTI$-3M

TCRX$-118M

EPS (TTM)

INTI$0.00

TCRX-$0.91

ROE (TTM)

INTI-33792.0%

TCRX-10872.0%

ROA (TTM)

INTI-12210.0%

TCRX-5447.0%

ROIC (TTM)

INTI-33792.0%

TCRX-8356.0%

Cash

INTI$516K

TCRX$100M

Debt

INTI$0

TCRX$33M

Net Cash/Debt

INTI$516K

TCRX$67M

Current Ratio (TTM)

INTI3.36x

TCRX3.37x

Quick Ratio (TTM)

INTI2.95x

TCRX3.23x

Debt/Equity (TTM)

INTI0.00x

TCRX0.47x

Debt/Assets (TTM)

INTI0.0%

TCRX0.0%

Interest Coverage (TTM)

INTIN/A

TCRXN/A

Net Debt/EBITDA (TTM)

INTI0.00x

TCRX0.00x

Beta

INTI-0.79

TCRX1.19

52W Performance

INTI127.9%

TCRX-88.0%

YTD Performance

INTI108.5%

TCRX-76.7%

% from 52W High

INTI-21.0%

TCRX-90.7%

% from 52W Low

INTI180.0%

TCRX6.1%

Asset Turnover (TTM)

INTI0.50x

TCRX0.03x

FCF Yield (TTM)

INTI-19.1%

TCRX-761.5%

Earnings Yield (TTM)

INTI-15.9%

TCRX-756.8%

Dividend Yield (TTM)

INTIN/A

TCRXN/A

Rule of 40

INTI0.0

TCRX-1,663.4

EV/GP/RG

INTIN/A

TCRXN/A

Ticker research

View INTI research View TCRX research

Metric	INTI Inhibitor Therapeutics Inc	TCRX TScan Therapeutics Inc
Market & Valuation
Market Cap	$17M	$16M
Enterprise Value	$16M	$-52M
Price	$0.10	$0.24
P/E Ratio	N/A	N/A
P/S Ratio	4.25x	2.19x
EV/Sales	4.12x	-7.29x
EV/EBITDA	1.61x	0.00x
P/B Ratio	4,922.43x	0.31x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.09x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	8.85x
Revenue & Growth
Revenue (TTM)	$0	$7M
Revenue Growth (YoY)	N/A	2.2%
Forward Rev Growth	0.0%	42.6%
Profitability
Gross Margin (TTM)	20.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1626.5%
Net Margin (TTM)	0.0%	-1655.4%
FCF Margin (TTM)	N/A	-1665.6%
Net Income (TTM)	$-3M	$-118M
FCF (TTM)	$-3M	$-118M
EPS (TTM)	$0.00	-$0.91
ROE (TTM)	-33792.0%	-10872.0%
ROA (TTM)	-12210.0%	-5447.0%
ROIC (TTM)	-33792.0%	-8356.0%
Financial Health
Cash	$516K	$100M
Debt	$0	$33M
Net Cash/Debt	$516K	$67M
Current Ratio (TTM)	3.36x	3.37x
Quick Ratio (TTM)	2.95x	3.23x
Debt/Equity (TTM)	0.00x	0.47x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.79	1.19
52W Performance	127.9%	-88.0%
YTD Performance	108.5%	-76.7%
% from 52W High	-21.0%	-90.7%
% from 52W Low	180.0%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.03x
FCF Yield (TTM)	-19.1%	-761.5%
Earnings Yield (TTM)	-15.9%	-756.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,663.4
EV/GP/RG	N/A	N/A
Ticker research	View INTI research	View TCRX research